Cardiovascular disease (CVD) and cancer are the two leading causes of mortality globally. Emerging evidence suggests a relationship between CVD and cancer, which share common risk factors and genetics and molecular mechanisms. Furthermore, cancer survivors have an increased risk for CVDs, mainly because of the toxicities of cancer treatment. It has been reported that cancer treatment with conventional chemotherapy (anthracyclines, HER2 antagonists, VEGF/TKI inhibitors) causes severe cardiovascular adverse events, including coronary artery disease, hypertension, QT prolongation, cardiac dysfunction, and heart failure. In addition, recent studies suggest that cancer immunotherapy (PD-1/PD-L1 and CTLA-4 Inhibitors) leads to cardiomyocyte damage and myocarditis with an incidence of 0.04-1.14% and a mortality of 25-50%. Moreover, the use of combination immune check inhibitor therapy has more frequent and severe myocarditis. However, the molecular and pathophysiologic mechanisms underlying the cardiovascular toxicity of cancer therapy are poorly understood. Therefore, it is crucial to clarify the pathophysiology of cardiovascular toxicity induced by cancer therapy and explore novel diagnostic and therapeutic approaches to improve cardiac function and prevent cardiovascular injury.
The goal of this Research Topic is to investigate the relationship between cancer treatment and cardiovascular toxicity in the development and progression of CVDs; and to explore new approaches for early diagnosis, monitoring, and treatment of cancer therapy-induced cardiovascular toxicity, as well as to identify the mechanisms underlying these adverse cardiovascular effects induced by chemotherapy and immunotherapy.
This Research Topic welcomes submissions of Original Research, Clinical Trial, Review articles, Case Report, or other article types presenting studies on basic and clinical investigations in the filed of Cardio-oncology, but not limited to, the following subtopics:
1. New cardiovascular manifestations amid cancer treatments.
2. The molecular mechanisms of cardiovascular toxicities induced by chemotherapy, immunotherapy, and radiotherapy, including cardiomyopathy, arrhythmias. Myocarditis heart failure, coronary artery disease, hypertension, and renal disease.
3. New therapeutic strategies to prevent cardiovascular injury from chemotherapy, immunotherapy, and/or radiation therapy. Novel approaches to mitigate the cardiovascular incidence and pathophysiological alterations after cancer therapies. Improved clinical guidelines for assessing cardiotoxicity during cancer treatments.
4. Novel clinical biomarkers (including blood or genomic biomarkers) and multimodality cardiac imaging technologies for cancer patients prone to cardiovascular toxicity.
Cardiovascular disease (CVD) and cancer are the two leading causes of mortality globally. Emerging evidence suggests a relationship between CVD and cancer, which share common risk factors and genetics and molecular mechanisms. Furthermore, cancer survivors have an increased risk for CVDs, mainly because of the toxicities of cancer treatment. It has been reported that cancer treatment with conventional chemotherapy (anthracyclines, HER2 antagonists, VEGF/TKI inhibitors) causes severe cardiovascular adverse events, including coronary artery disease, hypertension, QT prolongation, cardiac dysfunction, and heart failure. In addition, recent studies suggest that cancer immunotherapy (PD-1/PD-L1 and CTLA-4 Inhibitors) leads to cardiomyocyte damage and myocarditis with an incidence of 0.04-1.14% and a mortality of 25-50%. Moreover, the use of combination immune check inhibitor therapy has more frequent and severe myocarditis. However, the molecular and pathophysiologic mechanisms underlying the cardiovascular toxicity of cancer therapy are poorly understood. Therefore, it is crucial to clarify the pathophysiology of cardiovascular toxicity induced by cancer therapy and explore novel diagnostic and therapeutic approaches to improve cardiac function and prevent cardiovascular injury.
The goal of this Research Topic is to investigate the relationship between cancer treatment and cardiovascular toxicity in the development and progression of CVDs; and to explore new approaches for early diagnosis, monitoring, and treatment of cancer therapy-induced cardiovascular toxicity, as well as to identify the mechanisms underlying these adverse cardiovascular effects induced by chemotherapy and immunotherapy.
This Research Topic welcomes submissions of Original Research, Clinical Trial, Review articles, Case Report, or other article types presenting studies on basic and clinical investigations in the filed of Cardio-oncology, but not limited to, the following subtopics:
1. New cardiovascular manifestations amid cancer treatments.
2. The molecular mechanisms of cardiovascular toxicities induced by chemotherapy, immunotherapy, and radiotherapy, including cardiomyopathy, arrhythmias. Myocarditis heart failure, coronary artery disease, hypertension, and renal disease.
3. New therapeutic strategies to prevent cardiovascular injury from chemotherapy, immunotherapy, and/or radiation therapy. Novel approaches to mitigate the cardiovascular incidence and pathophysiological alterations after cancer therapies. Improved clinical guidelines for assessing cardiotoxicity during cancer treatments.
4. Novel clinical biomarkers (including blood or genomic biomarkers) and multimodality cardiac imaging technologies for cancer patients prone to cardiovascular toxicity.